NCT05723432View on ClinicalTrials.gov

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Melanoma
Interventions
DRUG

KD6001

KD6001 will be administered intravenously.

DRUG

Toripalimab

Toripalimab will be administered intravenously.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Shanghai Kanda Biotechnology Co., Ltd.

INDUSTRY